Read the latest research on Alzheimer's disease. Learn about Alzheimer's symptoms such as memory loss and senile dementia. Find out about Alzheimer's stages, causes and new treatments.
Updated: 14 min 37 sec ago
Researchers have been trying to figure out what regulates molecular circadian clocks, in search of new insights into diseases like Alzheimer's, cancer and diabetes. Until now, that research has focused on what is known as clock genes. But new research reveals the discovery of a new cog in the circadian clock - a genome-wide regulatory layer made up of small chains of non-coding nucleotides known as micro RNAS (miRNAs).
Scientists have announced a significant advance in our understanding of an early onset form of dementia that may also progress our understanding of conditions such as Alzheimer's disease. Adult onset Leukoencephalopathy with axonal Spheroids and Pigmented glia (ALSP) is an ultra-rare condition that manifests initially with psychiatric and behavioural changes in patients followed by a rapid progression of dementia in the third or fourth decade of life.
A new study found a specific Alzheimer's treatment is effective in male and not female mice, providing a window into the biology of the disease and the effectiveness of targeted treatments.
Researchers have identified the driving force behind a cellular process linked to neurodegenerative disorders such as Parkinson's and motor neuron disease.
Apathy -- a lack of interest or motivation -- could predict the onset of some forms of dementia many years before symptoms start, offering a 'window of opportunity' to treat the disease at an early stage, according to new research.
A team has uncovered that microglial cells constantly survey the brain to prevent spontaneous seizures. These findings could offer a new way to intervene in Alzheimer's disease, epilepsy, and autism.
Researchers have identified a family of enzymes whose inhibition both protects neurons and encourages their growth, a pathway to potential new treatments for neurodegenerative diseases from Alzheimer's to glaucoma.
The foods we eat may have a direct impact on our cognitive acuity in our later years, according to new research. The study is the first of its kind to connect specific foods with cognitive decline. The findings show cheese protected against age-related cognitive problems and red wine was related to improvements in cognitive function.
A research team has developed a diagnostic tool for the rare neurological disease amyotrophic lateral sclerosis (ALS). The study used the patented immuno-infrared sensor to analyze folding changes of proteins in the cerebrospinal fluid (CSF) of ALS patients after specific binding.
Today, a clinician can order a blood test to check a patient's cholesterol or hemoglobin A1c levels -- biomarkers that help predict an individual's risk of cardiovascular disease or diabetes, respectively. But despite decades of advances in the understanding of Alzheimer's disease (AD), a blood test for predicting its risk remains elusive. Imaging scans of the brain and lumbar punctures that collect cerebrospinal fluid can offer diagnoses, but such tests are expensive and cumbersome for patients. Two years ago, investigators reported the development of a blood test for a fragment of the protein tau, a hallmark of AD. Now, that test for levels of N-terminal fragment of tau (NT1) has been evaluated in participants in the Harvard Aging Brain Study (HABS), a cohort of cognitively normal, older adults who are followed closely over time. Researchers now report that baseline NT1 levels in the blood were highly predictive of the risk of cognitive decline and AD dementia.
Researchers have come one step closer toward understanding why some people become seriously ill or die from a common bacterium that leaves most people unharmed. The researchers linked RNA mutations within the bacterium Neisseria meningitidis to invasive meningococcal disease, marking the first time a non-coding RNA in a bacterium has been linked to disease progression.
Chemists have opened doors for fellow scientists to better address research questions related to Alzheimer's disease, the COVID-19 pandemic and more.
Researchers have found a novel form of the Alzheimer's protein tau in the fluid surrounding the brain and spinal cord. This form of tau -- known as MTBR tau -- indicates what stage of Alzheimer's a person is in and tracks with tangles of tau protein in the brain.
A new study on Alzheimer's disease has revealed a previously unknown biochemical cascade in the brain that leads to the destruction of synapses, the connections between nerve cells that are responsible for memory and cognition.
Researchers have found new forms of tau protein that become abnormal in the very early stages of Alzheimer's disease before cognitive problems develop. The scientists developed new tools to detect these subtle changes and confirmed their results in human samples.
A team of researchers has taken a major step toward understanding the mechanisms involved in the formation of large clumps of tau protein, a hallmark of Alzheimer's disease and several other neurodegenerative disorders.
Just a few doses of an experimental drug can reverse age-related declines in memory and mental flexibility in mice, according to a new study. The drug, called ISRIB, has already been shown in laboratory studies to restore memory function months after traumatic brain injury (TBI), reverse cognitive impairments in Down Syndrome, prevent noise-related hearing loss, fight certain types of prostate cancer, and even enhance cognition in healthy animals.
A form of artificial intelligence designed to interpret a combination of retinal images was able to successfully identify a group of patients who were known to have Alzheimer's disease, suggesting the approach could one day be used as a predictive tool, according to an interdisciplinary study.
A new study found that Medicare beneficiaries who go on to be diagnosed with dementia are more likely to miss payments on bills as early as six years before a clinical diagnosis.
A new study has found that among older Americans with cognitive impairment, the greater the air pollution in their neighborhood, the higher the likelihood of amyloid plaques - a hallmark of Alzheimer's disease. The study adds to a body of evidence indicating that pollution from cars, factories, power plants and forest fires joins established dementia risk factors like smoking and diabetes.